tbuckley/cabot-search huggingface dataset:
Editorial Board
Authors: Bruce Thiers, Dirk Elston, Detra Davis, Charlene Dundek, Jack Lesher, Nikki Levin, Mary Spellman, Jeffrey Weinberg, Dermatologic Surgery, Clifford Perlis, Julie Prendiville, Frcpc Dermatopathology, John Maize, Social Media, Emily Altman, Robert Dellavalle, J Smith, Editors Emeritus, Richard Dobson, Jeffrey Bernhard, Calvin Mccall, Brett Sloan, James Solomon, Stephen Tyring, George Hruza, Pediatric Dermatology, Kelly Cordoro, Dermatopathology Carlson, Tammie Ferringer, Cyberdermatology Consultant, Daniel Siegel, Clara Kim, Bryan Anderson, Salvador Arias-Santiago, Trisha Beute, John Binhlam, Diana Bolotin, Markus Braun-Falco, Nooshin Brinster, Patrick Carrington, Zoe Draelos, Nananamibia Duffy, Laura Ferris, David Fivenson, Joel Gelfand, Camille Introcaso, Nathaniel Jellinek, Jonathan Kantor, Matthew Kanzler, Kevin Kia, Kenneth Linden, Jason Lott, Omar Lupi, A2 December, J Am, Acad Dermatol
Journal: Journal of the American Academy of Dermatology (2016)
Modified antigen therapy aids allergy victims
Authors: W. A. Check
Journal: JAMA (1982)

Desensitization therapy for ragweed hay fever may become more effective and safer with newer forms of reagents, according to results presented at this year's meeting of the American Academy of Allergy and Immunology in Montreal. Furthermore, since effective desensitization is achieved with a much shorter course of these preparations, called modified antigens, the cost to the patient will be greatly reduced when they come on the market. The Food and Drug Administration is expected to approve modified antigens in the next few years. Their availability may extend the benefits of ragweed immunotherapy to many more of the estimated 15 million sufferers in the United States. <h3>Clinical Studies With Modified Antigens</h3> Roy Patterson, MD, and colleagues in the Department of Medicine at Northwestern University Medical School in Chicago have been working with a polymerized ragweed (PRW) antigen preparation for a number of years (<i>JAMA</i>[MEDICAL NEWS] 1980;243:1703-1704). At this year's meeting
Homeopathic Arnica for Prevention of Pain and Bruising: Randomized Placebo-Controlled Trial in Hand Surgery
Authors: C Stevinson, V S Devaraj, A Fountain-Barber, S Hawkins, E Ernst
Journal: Journal of the Royal Society of Medicine (2003)

Homeopathic arnica is widely believed to control bruising, reduce swelling and promote recovery after local trauma; many patients therefore take it perioperatively. To determine whether this treatment has any effect, we conducted a double-blind, placebo-controlled, randomized trial with three parallel arms. 64 adults undergoing elective surgery for carpal tunnel syndrome were randomized to take three tablets daily of homeopathic arnica 30C or 6C or placebo for seven days before surgery and fourteen days after surgery. Primary outcome measures were pain (short form McGill Pain Questionnaire) and bruising (colour separation analysis) at four days after surgery. Secondary outcome measures were swelling (wrist circumference) and use of analgesic medication (patient diary). 62 patients could be included in the intention-to-treat analysis. There were no group differences on the primary outcome measures of pain ( P=0.79) and bruising ( P=0.45) at day four. Swelling and use of analgesic medication also did not differ between arnica and placebo groups. Adverse events were reported by 2 patients in the arnica 6C group, 3 in the placebo group and 4 in the arnica 30C group. The results of this trial do not suggest that homeopathic arnica has an advantage over placebo in reducing postoperative pain, bruising and swelling in patients undergoing elective hand surgery.
Long-term Mortality Associated With Aprotinin Following Coronary Artery Bypass Graft Surgery—Reply
Authors: Dennis T. Mangano
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction: Sunscreens, photocarcinogenesis, melanogenesis, and psoralens
Journal: BMJ (1981)

CorrectionsHaemolytic disease of the newborn due to antibodies other than rhesus anti-DWe regret that an error appeared in the second paragraph of our leading article on "Haemolytic disease of the newborn due to antibodies other than rhesus anti-D" (22 August, p 514).Line 4 on page 515 should have read "of these, 70 (6 %,',) were due to anti-c.By 1974 prophylactic....
Fifth International Symposium on Flow Cytometry
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article Fifth International Symposium on Flow Cytometry Get access JNCI: Journal of the National Cancer Institute, Volume 64, Issue 5, May 1980, Page 1273, https://doi.org/10.1093/jnci/64.5.1273-b Published: 01 May 1980
Timely Toxicology
Authors: Jennifer F. Medlin
Journal: Environmental Health Perspectives (1999)

The ToxChip, a DNA microarray chip, allows the monitoring of the expression levels of thousands of different genes at a time, thereby condensing months of painstaking laboratory tasks into a day's work. For toxicology researchers in particular, this tool is important because it promises a more effective way to identify environmental hazards and their effects on DNA. The ToxChip, developed by NIEHS scientists J. Carl Barrett, Cynthia Afshari, and Emile F. Nuwaysir, could transform the way toxicologists approach environmental problems.
Increased urinary beta 2-microglobulin in cadmium exposure: dose-effect relationship and biological significance of beta 2-microglobulin.
Authors: K Tsuchiya, S Iwao, M Sugita, H Sakurai
Journal: Environmental Health Perspectives (1979)

A study on the general population from both cadmium-polluted and control areas and on cadmium alloy workers indicates that beta 2-MG in urine is very closely correlated with aging, but it indicates an association with cadmium exposure. However, the age factor is stronger than cadmium exposre in both polluted and control areas among persons without clinical proteinuria. On the other hand, cadmium exposure is most likely correlated with beta 2-MG even in nonpolluted areas. Thus it seems that there is no noneffect level of cadmium dose in affecting the elevation of beta 2-MG in urine. beta 2-MG in serum indicated a very close correlation with cadmium in blood among cadmium alloy workers. This may suggest that an increase of beta 2-MG in both blood and urine in an early stage of cadmium exposure is caused by the increased level of beta 2-MG in blood, which may be a result of stimulation due to cadmium, but not necessarily by the clinical dysfunction of reabsorption of beta 2-MG in the renal.
Clinical application of measurement of angiotensin-converting enzyme level
Authors: T. Shultz
Journal: JAMA (1979)

Assay of angiotensin-converting enzyme (ACE) in the sera of 69 patients demonstrated elevated levels in 19 of 22 (86%) of those with clinically active, biopsy-proved sarcoidosis. Patients with dormant sarcoidosis and generally those with various other disorders had normal levels. Elevated levels were also seen in six cases possibly representing sarcoid variants and in one case each of leprosy, carcinoma, tuberculosis, lymphomatoid granulomatosis, and immunoblastic sarcoma. Although ACE is sensitive to active sarcoidosis, the presence of false-positive findings limits its diagnostic usefulness to an adjunctive role; the assay should be combined with medical evaluation and tissue biopsy in selected cases. (<i>JAMA</i>242:439-441, 1979)
Chloroquine for Treatment of Acute Attacks of Vivax Malaria
Authors: Harry Most
Journal: JAMA (1984)

During the recent war an intensive search for new antimalarial drugs was conducted in the course of which thousands of chemical substances were investigated under the auspices of the Office of Scientific Research and Development. Studies were designed to find drugs which might have one or more of the following properties: (<i>a</i>) true causal prophylaxis, (<i>b</i>) ability to effect complete cure following treatment, (<i>c</i>) greater efficacy than quinacrine and quinine in suppression and (<i>d</i>) greater efficacy than quinine and quinacrine in the treatment of acute clinical attacks. The present report is concerned with chloroquine (SN 7618): 7-chloro-4-(4-diethylamino-1-methylbutylamino) quinoline, which is one of a series of new active antimalarial agents. Detailed studies of the antimalarial properties, pharmacology and toxicity of this drug have been carried out by numerous investigators, and undoubtedly the results of these studies will be generally available in the near future.<sup>1</sup>This paper is concerned principally with
Myeloperoxidase-positive inflammatory cells participate in bile duct damage in primary biliary cirrhosis through nitric oxide-mediated reactions
Authors: Chih-Te Wu, Jason P. Eiserich, Aftab A. Ansari, Ross L. Coppel, Sripriya Balasubramanian, Christopher L. Bowlus, Eric M. Gershwin, Judy Van De Water
Journal: Hepatology (2003)

Previous studies have suggested that increased nitric oxide (NO)–mediated products are found in the livers of subjects with primary biliary cirrhosis (PBC), but the mechanisms involved remain enigmatic. We took advantage of immunohistochemistry and several unique monoclonal antibodies to study inflammatory cells responsible for the generation of NO, the enzymes responsible for NO production, the expression of 3–nitrotyrosine, and the presence of CD68+ and/or myeloperoxidase (MPO) + cells. We examined a total of 113 liver specimens, including 64 with PBC, 19 with primary sclerosing cholangitis (PSC), 6 with non–A, non–B hepatitis, 6 with alcoholic liver disease, 4 with cryptogenic cirrhosis, 4 with biliary atresia, and 10 normal subjects. Twenty–two percent of PBC had elevated expression of 3–nitrotyrosine in their bile duct epithelial cells (BECs) ( P = .0316). Furthermore, the BECs in PBC also demonstrated apoptotic changes. MPO–positive inflammatory cells were also noted adjacent to the basement membrane. In contrast, the liver of normal subjects showed few apoptotic changes in the bile ducts, with no evidence of MPO staining in the portal area. Furthermore, sections from livers of subjects with stage I or stage II PBC demonstrated significantly increased inflammatory cell infiltration ( P = .0064) and elevated 3–nitrotyrosine expression in BECs ( P = .0246) compared with stage III and IV. The presence of 3–nitrotyrosine was closely associated with infiltrating CD68– and/or MPO–positive cells. There was also a stage–associated difference in the presence of bile duct infiltrating cells and 3–nitrotyrosine in PBC with an increase dominant in early stage disease. In conclusion, NO and reactive oxygen species, collectively determined as 3–nitrotyrosine, are associated with bile duct destruction in PBC and are particularly prevalent in early stage disease.
Vasculitis
Authors: Evelyn V. Hess
Journal: Annals of Internal Medicine (2002)

Medical Writings: Book Notes5 November 2002VasculitisEvelyn V. Hess, MDEvelyn V. Hess, MDUniversity of Cincinnati Medical Center, Cincinnati, Ohio.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-9-200211050-00036 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Ball GV and Bridges SL Jr., eds. 634 pages. Oxford, United Kingdom: Oxford Univ Pr; 2002. $168.95. ISBN 0192630539. Order phone 800-451-7556.Field of medicine: Rheumatology and immunology.Format: Hardcover book.Audience: Physicians in all fields, as vasculitis can occur in all body systems.Purpose: To provide guidance for physicians of various disciplines to diagnose vasculitis in all its forms and, therefore, provide better treatment and patient care.Content: The first chapter is an up-to-date review of the classification of vasculitic syndromes by the two editors. This is followed by four parts—Basic Science, Clinical Manifestations Common to Vasculitis, Imaging Studies ... Author, Article, and Disclosure InformationAuthors: Evelyn V. Hess, MDAffiliations: University of Cincinnati Medical Center, Cincinnati, Ohio. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2002Volume 137, Issue 9 Page: 782 Keywords Biopsy Diagnostic techniques Immunology Patients Radiologists Rheumatology Software tools Vasculitis ePublished: 5 November 2002 Issue Published: 5 November 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
STROKES
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blast Injuries of the Hand
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased blood levels of methyl tert-butyl ether but not of ethyl propionate during instillation with contact gallstone dissolution agents in the pig
Authors: O Esch
Journal: Hepatology (1993)

We performed experiments in anesthetized piglets with two cholesterol gallstone solvents, methyl tertbutyl ether and ethyl propionate, to determine whether blood levels of either solvent would increase during gallbladder instillation of these solvents under conditions simulating gallstone dissolution. The solvent was oscillated rapidly in and out of the gallbladder with a computer-controlled syringe pump; intraluminal pressure was set below the leakage pressure, and oscillating volume was set below the leakage volume to decrease loss of solvent into the intestine. Blood levels were measured with gas chromatography. Six piglets received methyl tert-butyl ether, and six piglets received ethyl propionate. During 2 hr of instillation with methyl tert-butyl ether, blood levels increased steadily to concentrations averaging 0.3 ml/L blood at 2 hr; during a 6-hr period of instillation, blood levels rose to above 0.4 ml/L blood. Replacement of methyl tert-butyl ether with saline solution in the gallbladder caused blood levels to decline gradually; plasma levels decreased by half in 90 min. In contrast, when ethyl propionate was infused for 2 or 6 hr, blood levels remained below the detection limit, probably because of high first-pass hepatic extraction. We conclude that, under conditions simulating those likely present in patients undergoing contact dissolution of gallbladder stones, the two solvents differ: Ethyl propionate is removed so rapidly from blood that its levels remain undetectable, whereas methyl tert-butyl ether levels in blood (and, presumably, peripheral tissues) increase continuously. If the absorption from the gallbladder and subsequent metabolism of ethyl propionate and methyl tert-butyl ether in human beings are similar to those of the piglet, side effects attributable to increased blood levels will be fewer if ethyl propionate is used than if methyl tert-butyl ether is used for contact dissolution of cholesterol gallstones. (HEPATOLOGY 1993;18:373–379).
A multicenter phase Ib/II study of DNA-PK inhibitor peposertib (M3814) in combination with capecitabine and radiotherapy in patients with locally advanced rectal cancer.
Authors: Paul Bernard Romesser, Emma B. Holliday, Tony Philip, Barbara Sarholz, Mirjam Kuipers, Almudena Rodriguez-Gutierrez, Ivan Diaz-Padilla, Eric David Miller
Journal: Journal of Clinical Oncology (2020)

TPS4117 Background: Preoperative chemo-radiotherapy with or without sequential chemotherapy, followed by surgical intervention, is standard of care for patients with locally advanced rectal cancer (LARC). However, 1/3 of these patients still develop distant metastases, indicating the need for more effective therapies. DNA-dependent protein kinase (DNA-PK) regulates a key DNA damage repair pathway for double-strand break repair. Peposertib (M3814), a potent, selective, orally administered DNA-PK inhibitor, has been shown to potentiate the effect of ionizing radiation in a human colon cancer xenograft model and several colon cancer cell lines. Peposertib is being investigated in several different trials across multiple indications. This Phase Ib/II study (NCT03770689) aims to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of the neoadjuvant treatment combination of peposertib, capecitabine, and radiotherapy (RT) in patients with LARC. Methods: Patients aged ≥18 years with histologically confirmed and resectable Stage II/III rectal adenocarcinoma are eligible. Induction chemotherapy is permitted, but residual disease must first be documented by MRI, digital rectal examination and endoscopy. Patients who received other anticancer therapies or those with prior pelvic RT are excluded. During open-label Phase Ib (open), 18–30 patients (n = 3 per cohort) are due to receive peposertib + capecitabine (orally, 825 mg/m 2 twice daily [BID]) + RT (45–50 Gy), 5 days/week. Peposertib 50 mg once daily (QD) is the starting dose. Additional dose levels will be between 100─800 mg QD. Dose escalation is determined by the safety monitoring committee and guided by a Bayesian 2-parameter logistic regression model. At Phase II (planned), 150 patients will be randomized (1:1) to receive oral capecitabine (825 mg/m 2 BID) + RT (45–50 Gy), with either oral peposertib (recommended phase II dose [RP2D]) or placebo, QD for 5 days/week. Primary objectives are to define a maximum tolerated dose and RP2D (Phase Ib), and to evaluate the efficacy of peposertib + capecitabine + RT in terms of pathological/clinical complete response (Phase II). Secondary objectives include assessment of antitumor activity (Phase Ib), quality of life outcomes (Phase II), and PK of peposertib, and the safety and tolerability of the combination therapy (both phases). One patient has received peposertib 50 mg QD and six patients have received peposertib 100 mg QD. Patients are currently receiving peposertib 150 mg QD. Clinical trial information: NCT03770689 .
Rehabilitation Medicine
Authors: Edward A. Edwards
Journal: JAMA (1977)

Just published is a new edition of Rusk's classic comprehensive work, encompassing most aspects of rehabilitation medicine, mainly as it pertains to patients in outpatient or rehabilitation facilities. There is diminished emphasis on the more acute problems encountered in a general hospital setting. As in former editions, an excellent philosophy pervades this book. For example, if treatment is to be effective, the physician must recognize such attitudes of the patient as dependence or hostility. The patient must participate actively in his rehabilitation. We must become widely enthusiastic about ingenious organic explanations of pain, but must recognize many new techniques of treatment as variations of desirable positive suggestion. Again we are taught that rehabilitation is everybody's business, particularly that of the patient's own physician, regardless of his specialty, and that the need to help the patient in his everyday personal and humble tasks must not be beneath our scope.
Adenoid cystic carcinoma (cylindroma) of the trachea masquerading as asthma
Authors: A. Baydur
Journal: JAMA (1975)

A 40-year-old woman was admitted with upper airway obstruction; chest roentgenogram with tomograms, laryngoscopy, and bronchoscopy verified the presence of a subglottic tumor. Spirometry disclosed a maximum inspiratory flow rate more reduced than the maximum expiratory flow rate, suggestive of upper airway obstruction. The pathologic conditions were consistent with cystic adenoid carcinoma (cylindroma) of the trachea. The patient underwent tracheostomy and total laryngectomy with an uneventful recovery. No evidence of local extension or distant metastases were evident at time of surgery. (<i>JAMA</i>234:829-831, 1975)
Antisecretory drugs and gastric cancer.
Authors: M J Daly, A Pottage
Journal: BMJ (1985)

attendance-the existence of long established diabetic clinics in two big hospitals within 4 kilometres, relatively well informed town folk, and the belief that Ayurveda had very little to offer in the treatment of diabetes.Hence, the factors that influence patients in their choice between Ayurvedic and Western type medicine are rather complex and need a deeper understanding of the way of life in different parts of Sri Lanka and the types of disease prevalent.
A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting (ESPRESSO-02/HGCSG1602)
Authors: M. Nakamura, T. Muranaka, M. Yagisawa, Y. Kawamoto, S. Yuki, A. Ishiguro, M. Dazai, S. Sogabe, K. Harada, Y. Kobayashi, T. Miyagishima, N. Okamura, Y. Tsuji, S. Terae, K. Ono, Y. Komatsu
Journal: Annals of Oncology (2018)